Breakthrough sleep apnea medication AD109 shows promising results in phase 3 trials, potentially helping 30 million Americans with the condition.

Medically reviewed by Susan Russell, MD Obstructive sleep apnea is one of the most common types of sleep apnea, affecting 936 million adults worldwide. If you have a close family member with the ...

Medically reviewed by Sanja Jelic, MD Obstructive sleep apnea (OSA) is the most common form of sleep apnea.Central sleep apnea (CSA) is a less common but serious condition.Both OSA and CSA are ...

Credit: Getty Images Obstructive sleep apnea may significantly increase the risk for coronary artery disease, atrial fibrillation, cerebrovascular accident, and congestive heart failure. Obstructive ...

It could be a game-changer for the millions of Americans who suffer from sleep apnea. A new first-of-its-kind pill could ...

Tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63% (about 30 fewer events per hour), meeting all primary and key secondary endpoints in two phase 3 clinical trials Tirzepatide ...

Biotech firm Apnimed plans to seek FDA approval for its sleep apnea drug, with market availability expected by 2027 ...

ORLANDO -- Tirzepatide (Zepbound) improved symptoms of moderate-to-severe obstructive sleep apnea (OSA) in people with obesity, regardless of positive airway pressure (PAP) use, the phase III SURMOUNT ...

The global sleep apnea implants market is projected to expand at a compound annual growth rate (CAGR) of approximately 10% ...

The MarketWatch News Department was not involved in the creation of this content. Women with sleep apnea face misdiagnosis and delayed treatment due to a lack of knowledge by physicians of the ...

The sleep apnea devices market is primarily driven by the rising prevalence of obstructive sleep apnea (OSA) and related risk factors, as well as by growing public health initiatives, awareness ...